Results 91 to 100 of about 166,627 (157)

Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in seropositive solid organ transplant recipients: anti-AD2 levels correlate with protection from viraemia [PDF]

, 2018
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection.
Reeves, M, McLean, G, Smith, C, Kropff, B, Mach, M, Baraniak, IA, Milne, RSB, Griffiths, P, Pichon, S   +8 more
core   +1 more source

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

, 2015
The early life influenza disease burden calls for more effective vaccines to protect this vulnerable population. Influenza vaccines including the MF59 oil-in-water adjuvant induce higher, broader, and more persistent Ab responses in adults and ...
Auderset, Floriane, Del Giudice, Giuseppe, Mastelic-Gavillet, Beatris, Tregoning, John S, Seubert, Anja, Lambert, Paul Henri, de Gregorio, Ennio, Siegrist, Claire-Anne, Eberhardt, Christiane Sigrid, Castellino, Flora, Mastelic Gavillet B, Eberhardt CS, Lambert PH, Castellino F, Auderset F, Siegrist CA, Seubert A, de Gregorio E, Tregoning JS, Del Giudice G   +19 more
core   +1 more source

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

, 2023
Vaccination against human cytomegalovirus (CMV) infection remains high priority. A recombinant form of a protein essential for CMV entry, glycoprotein B (gB), demonstrated partial protection in a clinical trial (NCT00299260) when delivered with the MF59 ...
C Atkinson (9629672), P Holenya (21407363), A Lankina (21407357), T Mahungu (12638086), Z Moulder (21407360), MB Reeves (21407366), IA Baraniak (21407354), G Tang (4173847), PD Griffiths (14814940), AC Gomes (21407351), Florian Kern (4461943)   +10 more
core  

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases

, 2007
The ability of influenza vaccination to provide cross-protection against heterovariant influenza strains was evaluated in a double-blind, randomized, trial in north-east Italy during the winter of 2005-2006.
FLOREANI, ANNAROSA, BALDO, VINCENZO, TRIVELLO R., BALDOVIN, TATJANA, FRAGAPANE E   +4 more
core   +1 more source

Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice. [PDF]

Oncotarget, 2017
Ou H, Yao W, Yu D, Weng T, Wang FXC, Wu X, Wu H, Cheng L, Lu X, Wu N, Chen H, Li L, Yao H.   +12 more
europepmc   +1 more source

RAD001-Adjuvanted Influenza Vaccine Synergizes With Anti-Programmed Cell Death Protein 1 Therapy to Enhance Antitumor Immunity in Programmed Cell Death Ligand 1-Low Murine Lung Cancer. [PDF]

World J Oncol
Ou HL, Sun J, Wu SB.
europepmc   +1 more source

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E. [PDF]

Front Immunol
Quan Y, Zhang S, Wang W, Wang Y, Xu K, Wang K, Wan W, Nie J.   +7 more
europepmc   +1 more source

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology. [PDF]

Hum Vaccin Immunother
Zarrinpanah T, Mashhadi Abolghasem Shirazi M, Modarressi SMH, Haghighat S.   +3 more
europepmc   +1 more source

Systemic Transcriptional Responses to Clinical Vaccine Formulations and Live-Attenuated Vaccination: Comparative Kinetics and Hypotheses for Therapeutic Cancer Vaccine Monitoring. [PDF]

Vaccines (Basel)
Goldman CK.
europepmc   +1 more source

Valutazione dell'immunogenicità del vaccino influenzale adiuvato con MF59 in un campione di anziani istituzionalizzati

, 2004
nello studio viene valutto su un campione di anziani istituzionalizzati la maggior efficacia del vaccino adiuvato con MF59 in termini di media geometrica dei titoli anticorpali tipo specifici pre e post vaccinazioneObjective: In elderly people, because ...
C. Gonella, M. Talassi, C. Mensi, F. Zaffanella, M. Giacomazzi, A. Giani, A. Zanoni, F. Pregliasco, D. Tinazzi, G. Anselmi   +9 more
core